Patients on drug therapy causing immunosuppression have an increased risk of infections. Since infections have a potential to trigger acute porphyric attacks vigilance is motivated regarding signs or symptoms of infection and/or possible symptoms of a porphyric attack

Infections are common in patients using immunosuppressants and since infections might trigger an acute porphyric attack, vigilance regarding signs and symptoms of an infection and/ or a porphyric attack is recommended.

Etanercept is not metabolized by cytochrome P450 enzymes. No pharmacokinetic porphyrinogenic effects are suspected.

Etanercept is a recombinant form of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) fused to the Fc fragment of human immunoglobulin G1 (IgG1).

Etanercept is a biologic response modifier used in the treatment of moderately to severely active rheumatoid arthritis and active and progressive psoriatic arthritis. It is administered by subcutaneous injection.

Since etanercept is a fusion glycoprotein, consisting entirely of human protein components, it is expected to undergo proteolysis. Hence studies were not conducted. The cytochrome P450 system and other commonly used metabolic pathways are not involved in the metabolism of etanercept, so there is little potential of metabolic drug interactions. In clinical trials, no interactions have been observed when Enbrel was administered with glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, or methotrexate.